Sequantrix GmbH – Trademark Portfolio
Entity Type: 16
Sequantrix GmbH holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include SEQUANTRIX and FIBRODECODER.
Pauwelsstrasse 17
52074 Aachen
Showing of trademarks Trademarks
Trademark Classifications
Sequantrix GmbH's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Sequantrix GmbH have?
Sequantrix GmbH has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Sequantrix GmbH file in?
Sequantrix GmbH files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Sequantrix GmbH's most well-known trademarks?
Sequantrix GmbH's registered trademark portfolio includes well-known marks such as SEQUANTRIX and FIBRODECODER. These are among 2 currently registered trademarks in the portfolio.
What is Sequantrix GmbH's trademark registration success rate?
Sequantrix GmbH has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.